Purpose The addition of PARP inhibitors to chemotherapy has been assessed in> 80 clinical
trials across multiple malignancies, on the premise that PARP inhibitors will increase …

In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer
therapies. The discovery of a growing number of synthetic lethal targets has led to a …

The emergence of resistance to PARP1 inhibitors poses a current therapeutic challenge,
necessitating the development of novel strategies to overcome this obstacle. The present …

Purpose To evaluate the association between industry payments to physicians related to
poly (ADP-ribose) polymerase inhibitors (PARPis) and physicians' prescribing behaviors for …

Simple Summary Survival for many pediatric cancers has improved over recent decades.
However, for pediatric patients with solid tumors that fail to respond to standard therapies, or …

Targeting oncogene addictions have changed the history of subsets of malignancies and
continues to represent an excellent therapeutic opportunity. Nonetheless, alternative …

PARP7 has been recently identified as an effective drug target due to its specific role in
tumor generation and immune function recovery. Herin, we report the discovery of …

Resistance to platinum‐based chemotherapies remains a significant challenge in advanced‐
stage high‐grade serous ovarian carcinoma, and patients with malignant ascites face the …

Purpose A multi-site Phase I trial was conducted to determine the safety, maximum tolerated
dose, and pharmacokinetics (PK) of Veliparib, a Poly (ADP-ribose) polymerase [PARP] …

Simple Summary This multicenter, retrospective analysis had the objective of comparing the
efficacy of PLD-Trabectedin in patients who had already been treated with PARP-I (cases) …